<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00713934</url>
  </required_header>
  <id_info>
    <org_study_id>Liver-001</org_study_id>
    <nct_id>NCT00713934</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Stem Cells in Cirrhosis Patients</brief_title>
  <official_title>Autologous Transplantation of Bone Marrow Derived CD 133 Positive Stem Cell and Mono Nuclear Cell (MNC) Transplantation in Patients With Decompensate Cirrhosis: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Small Business Developing Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver cirrhosis (LC) is the end stage of chronic liver disease. The liver transplantation is
      one of the only effective therapies available to such patients. However, lack of donors,
      surgical complications, rejection, and high cost are it`s serious problems. The potential for
      stem cells in bone marrow (BM) to differentiate into hepatocytes cells was recently
      confirmed. Moreover, BMC transplantation has been performed to treat hematological diseases,
      and several clinical studies have applied BMC injection to induce regeneration of myocardium
      and blood vessels. In this study we will evaluate safety and feasibility of autologous bone
      marrow mono nuclear (BM-MNC) and enriched CD133+ hematopoietic stem cell transplantation
      through the portal vein in patients with decompensate cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BM (200 ml) will be harvested from the iliac crest according to standard procedures under
      general anesthesia and is collected in plastic bags containing anti coagulant. After
      precipitation of red blood cells, Low density mononuclear cells will be collected by
      centrifugation in Ficoll-Paque density gradient. For CD133+ cells separation the CliniMACS
      instrument will be used. Cells are injected via portal vein under sonography monitoring.
      After cell therapy, patients are followed up every week for 4 weeks, and laboratory data are
      analyzed for 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver function test</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MELD score</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cirrhosis mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Stem Cell Transplantation</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD133</intervention_name>
    <description>portal vein infusion of CD133+ cells</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BM-MNC</intervention_name>
    <description>portal vein infusion of BM-MNC</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver biopsy showing histological Cirrhosis, grade B or C (Child-Pugh score)

          -  Alkaline phosphatase between 2 X to 3X normal value

          -  liver Cirrhosis in Sonography study

          -  Incomplete response to UDCA after 6 months of treatment.

          -  Negative pregnancy test (female patients in fertile age)

          -  written consent

        Exclusion Criteria:

          -  Presence of active hepatic encephalopathy

          -  Refractory ascites

          -  Evidences of active autoimmune liver disease (e.g. gamma globulin of more than 2 times
             of upper limit of normal, and ALT &gt; 3 times normal in patients with autoimmune
             hepatitis)

          -  Hepatocellular carcinoma or other malignancies

          -  sepsis

          -  Presence of significant extrahepatic biliary disease (e.g. CBD stone, PSC, etc.)

          -  HIV, HBV or HCV infection

          -  Cardiac, renal or respiratory failure

          -  Active thrombosis of the portal or hepatic veins

          -  INR&gt;2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gorabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Royan institute, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malekhosseini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Liver Transplantation Research Center, Shiraz, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hossein Baharvand, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royan institute, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saman Nikeghbal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liver Transplantation Research Center, Shiraz, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Royan institute, Tehran, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liver Transplant Research Center</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <zip>1665659911</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.royaninstitute.org</url>
    <description>Royan Institute</description>
  </link>
  <link>
    <url>http://www.sums.ac.ir</url>
    <description>Shiraz University Of Medical Sciences, Transplantation Research center</description>
  </link>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2008</study_first_submitted>
  <study_first_submitted_qc>July 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2008</study_first_posted>
  <last_update_submitted>October 1, 2011</last_update_submitted>
  <last_update_submitted_qc>October 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autologous Bone marrow stem cells</keyword>
  <keyword>Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

